TY - JOUR
T1 - Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation
AU - Tsirigotis, P.
AU - Danylesko, I.
AU - Gkirkas, K.
AU - Shem-Tov, N.
AU - Yerushalmi, R.
AU - Stamouli, M.
AU - Avigdor, A.
AU - Spyridonidis, A.
AU - Gauthier, J.
AU - Goldstein, G.
AU - Apostolidis, J.
AU - Mohty, M.
AU - Shimoni, A.
AU - Nagler, A.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.
AB - In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.
UR - http://www.scopus.com/inward/record.url?scp=84968586418&partnerID=8YFLogxK
U2 - 10.1038/bmt.2016.129
DO - 10.1038/bmt.2016.129
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 27183095
AN - SCOPUS:84968586418
SN - 0268-3369
VL - 51
SP - 1313
EP - 1317
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 10
ER -
